Angioedema

Subscribe to Selected New Research on Angioedema

1147 relevant articles (32 outcomes, 61 trials/studies) found for this Disease

Description: Swelling involving the deep DERMIS, subcutaneous, or submucosal tissues, representing localized EDEMA. Angioedema often occurs in the face, lips, tongue, and larynx.

Also Known As:

Angioneurotic Edema; Angioedemas; Angioneurotic Edemas; Edema, Angioneurotic; Edema, Quincke's; Edemas, Angioneurotic; Giant Urticaria; Giant Urticarias; Quincke Edema; Quinckes Edema; Urticarias, Giant; Quincke's Edema; Urticaria, Giant

Relationship Network

Disease Context: Research Results

Cardiovascular Diseases: 18509

Vascular Diseases: 7181

Angioedema: 1147

Hereditary Angioedema: 386

Skin and Connective Tissue Diseases

Skin Diseases: 5943

Vascular Skin Diseases: 2

Urticaria: 3299

Angioedema: 1147

Hereditary Angioedema: 386

Immune System Diseases: 1236

Hypersensitivity: 36014

Immediate Hypersensitivity: 1236

Urticaria: 3299

Angioedema: 1147

Hereditary Angioedema: 386

Related Diseases

1.	Urticaria (Hives)
2.	Hereditary Angioedema
3.	Pruritus (Itching)
4.	Syndrome
5.	Hypotension (Low Blood Pressure)

Experts

1.	Adam, Albert: 5 articles (01/2008 - 06/2002)
2.	Cicardi, Marco: 5 articles (09/2006 - 08/2002)
3.	Agostoni, Angelo: 5 articles (10/2005 - 10/2002)
4.	Brown, Nancy J: 4 articles (01/2008 - 02/2002)
5.	Cugno, Massimo: 4 articles (10/2005 - 08/2002)
6.	Kojda, G: 3 articles (08/2007 - 02/2005)
7.	Hoffmann, T K: 3 articles (08/2007 - 02/2005)
8.	Bas, M: 3 articles (08/2007 - 02/2005)
9.	Sica, Domenic A: 3 articles (01/2007 - 09/2002)
10.	Davis, Alvin E: 3 articles (11/2006 - 12/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Angioedema:

1.	Danazol (Azol)FDA LinkGeneric 05/01/2002 - "The danazol treatment relieved the symptoms of angioedema and increased the C1 INH activity and concentration with the normalization of CH50, C1q and C4 levels" 04/01/1990 - "She responded well to danazol and had no further attacks of angioedema." 05/01/2004 - "Because of the danger of angioedema that might be expected following chemo-radiotherapy, he was treated with danazol" 11/01/2003 - "The angioedema was controlled with Danazol and Stanasol" 06/01/2003 - "The angioedema was controlled with Danazol and Stanasol" Order ALL the reference details at left...
2.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 07/01/1996 - "Delayed onset of angioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature." 12/01/2007 - "STUDY DESIGN AND SETTING: Retrospective chart review of patients taking ACE inhibitors who presented to the emergency department with angioedema between December 1999 and July 2004 (n = 228)" 07/01/1997 - "RESULTS: Of the 40 patients presenting with angioedema in this study, 15 cases were caused by ACE inhibitors" 07/01/1993 - "The purpose of this study was to establish what proportion of patients who present to the emergency department (ED) with angioedema were concomitantly taking any of the ACE inhibitors and to show how this group differed in presentation and response to treatment from the larger population of patients with non-ACE inhibitor-related angioedema" 02/21/1989 - "Angioedema, a recognized adverse effect of ACE inhibitors, was not seen in the clinical trials reviewed here" Order ALL the reference details at left...
3.	mizolastine (Zolim)IBA 03/01/2000 - "Clinical assessment also indicated that itch intensity and angioedema were improved by mizolastine, and the improvement was sustained throughout the trial" 04/01/2000 - "In addition mizolastine demonstrated a superiority in prick tests, beneficial effects on angioedema and seemed to provide a faster onset of action." 01/01/1999 - "Angioedema was improved to a clinically significant extent with mizolastine, and loratadine compared with placebo in those patients who had this symptom before treatment" 04/01/2000 - "Mizolastine had a positive effect on angioedema (85% CI 95% [0.69-1.00]) of patients improved compared with 75% (CI 95% [0.59-0.91]) of the loratadine group and the differential reduction of the mean total duration of episodes in the mizolastine group was higher when compared with the loratadine group (from 13.7 +/- 33.5 hours on day 0 to 5.1 +/- 9.0 hours over the treatment period and from 8.2 +/- 8.8 hours on day 0 to 5.1 +/- 7.8 hours over the treatment period for mizolastine and loratadine, respectively)" Order ALL the reference details at left...
4.	SteroidsIBA 08/01/2001 - "All patients were treated with steroids and exhibited a good response, without relapse of angioedema and with normalization of plasma levels of C1-INH" 05/01/2001 - "A 35- and a 29-year-old woman presented with longstanding recurrent angioedema refractory to therapy with steroids and antihistaminic drugs" 07/01/1991 - "However, several additional diagnostic possibilities should be pursued in patients with angioedema, such as hereditary angioedema caused by C1-esterase inhibitor deficiency, because anabolic steroids are effective in the treatment of these conditions." 01/01/2008 - "PATIENTS AND METHODS: This single-centre prospective study included adults (1) presenting chronic urticaria as defined by the French consensus conference committee on chronic urticaria (2003), (2) exhibiting at least two of the following three criteria: sleep disturbance due to itching, repeated angioedema, general symptoms; (3) unresponsive or mildly improved by antihistaminic (anti-H1) therapy; (4) receiving oral steroids at least three days per month" 01/01/1976 - "Our patient and those of Agnello et al. had identical clinical symptoms such as erythema multiforme, arthralgias and angioneurotic edema and both differed from systemic lupus erthematosus in several important points, i.e., in spite of marked hypocomplementemia the nephropathy is not prominent and it needs high-dose steroids to eliminate the clinical and serological abnormalities" Order ALL the reference details at left...
5.	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 02/01/2005 - "AIMS: This study was designed to identify new factors which may contribute to angiotensin-converting-enzyme-inhibitor (ACEI)-induced angioedema" 08/01/2004 - "STUDY OBJECTIVE: To evaluate the incidence of airway compromise, clinical presentation and morbidity of angiotensin-converting enzyme inhibitor (ACEI)-related angioedema (AE)" 12/01/1999 - "Transient myocardial dysfunction associated with angiotensin-converting enzyme inhibitor-induced angioedema: recognition by serial echocardiographic studies." 07/01/1996 - "OBJECTIVE: To study the association of race and other patient characteristics associated with angiotensin converting enzyme (ACE) inhibitor-associated angioedema" 11/01/2008 - "Angioedema is a side effect that is often associated with the use of angiotensin-converting enzyme (ACE) inhibitor medications" Order ALL the reference details at left...
6.	BradykininIBA 05/01/2008 - "ACEi induce angioedema by increasing the levels of bradykinin" 01/01/2008 - "findings indicate bradykinin, a product of contact system activation, as the primary mediator of angioedema in patients with C1-inhibitor deficiency" 11/01/2007 - "Inhibited bradykinin degradation leads to an unphysiological enhanced bradykinin plasma level with vascular leakage and, consequently, to angioedema" 11/01/2007 - "Angioedema is caused by: 1. a decreased degradation of bradykinin, 2. a defect in C 1-esterase-inhibitor with the increased generation of bradykinin or 3. other trigger mechanisms as food, pollen and stress" 08/01/2007 - "Nonallergic angioedema: role of bradykinin." Order ALL the reference details at left...
7.	omapatrilatIBA 02/01/2004 - "Omapatrilat, an agent under development, has been shown to have significantly greater antihypertensive efficacy than existing agents, but may also carry increased risk of angioedema" 08/01/2003 - "The results of the OCTAVE trial confirmed the antihypertensive efficacy of omapatrilat, but at the price of an angioedema rate more than threefold higher than that of an ACE inhibitor in the overall population (2.17% vs 0.68%), and close to fourfold higher in the black population" 02/01/2004 - "Two omapatrilat-treated subjects experienced angioedema with airway compromise, which was successfully treated" 08/01/2003 - "Because angioedema is probably a class side effect of vasopeptidase inhibitors, the higher incidence of this potentially life-threatening complication with omapatrilat has likely stopped the development of this new class of agents" 11/01/2002 - "The worrying trend was however, that angioedema was more common with Omapatrilat; 24 (0.8%) versus 14 cases (0.5%).The OCTAVE (Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril) study was also presented at this time" Order ALL the reference details at left...
8.	Histamine H1 Antagonists (Antihistamines)IBA 07/01/1991 - "Treatment of these forms of angioedema depends on identifying and avoiding the cause, induction of tolerance, or symptomatic treatment with systemic antihistamines." 01/01/1985 - "The H1 antihistamines are used for the treatment of both acute and chronic angioedema" 01/01/1993 - "Their efficacy combined with greatly reduced sedating and anticholinergic side effects makes the new class of H1 antihistamines the first-line treatment in the management of urticaria and mild angioedema" 01/01/2002 - "Antihistamines in urticaria and angioedema." 10/01/2001 - "H(1)-receptor antagonists (antihistamines) are the major class of therapeutic agents used in the management of urticaria and angioedema" Order ALL the reference details at left...
9.	Antihypertensive Agents (Antihypertensives)IBA 08/01/2008 - "Twenty-four percent of hospitalizations for angioedema were coded for an adverse effect due to cardiovascular or antihypertensive agents" 06/01/2008 - "We estimate that 58.3% of angioedema in patients starting antihypertensives was related to ACE" 09/01/2004 - "Antihypertensives and angioedema." 12/01/1991 - "Precipitation of angioedema by antihypertensive drugs." 02/01/1996 - "These new antihypertensive agents also have uricosuric actions and are well tolerated, with a low incidence of cough and angioedema, side effects that are seen with angiotensin-converting enzyme inhibitors" Order ALL the reference details at left...
10.	Loratadine (Alavert)FDA Link 06/01/1993 - "In a randomized double-blind, crossover study, we evaluated the effects of loratadine and placebo administered once daily in 184 food intolerant patients affected by urticaria-angioedema" 06/01/1993 - "Effectiveness of loratadine vs. placebo in the treatment of urticaria-angioedema syndrome in patients with food allergy]" 01/01/1999 - "Angioedema was improved to a clinically significant extent with mizolastine, and loratadine compared with placebo in those patients who had this symptom before treatment" 04/01/2000 - "Mizolastine had a positive effect on angioedema (85% CI 95% [0.69-1.00]) of patients improved compared with 75% (CI 95% [0.59-0.91]) of the loratadine group and the differential reduction of the mean total duration of episodes in the mizolastine group was higher when compared with the loratadine group (from 13.7 +/- 33.5 hours on day 0 to 5.1 +/- 9.0 hours over the treatment period and from 8.2 +/- 8.8 hours on day 0 to 5.1 +/- 7.8 hours over the treatment period for mizolastine and loratadine, respectively)" Order ALL the reference details at left...

Therapies and Procedures

1.	Renal Dialysis (Hemodialysis) 10/01/2007 - "These drugs have a variety of acute adverse effects, the nature of which depends on the clinical context, and which include angioedema, anaphylactoid reactions in hemodialysis patients, and severe hypotensive reactions during blood product transfusions" 11/01/2006 - "In conclusion, this paper highlights the complexity of HSR in hemodialysis, suggesting, as with angioedema, that these rare, but life-threatening adverse events are governed by several metabolic and genetic factors." 08/01/2004 - "Though the therapeutic administration of C1-inhibitor concentrate was effective in controlling her angioedema, seemed ineffective in preventing her from developing ESRD requiring hemodialysis treatment" 01/01/1990 - "Only 3 among the 7 positive patients had adverse reactions related to the hemodialysis (one suffered from itching, one from urticaria and the third from angioedema and hypotension)" 09/01/2005 - "This is the first report of isolated visceral angioneurotic edema induced by lisinopril and/or valsartan in a patient on maintenance hemodialysis and, moreover, with the association of accessory pancreas of the jejunum." Order ALL the reference details at left...
2.	Immunotherapy 07/01/1997 - "Six patients were re-stung while receiving venom immunotherapy: only one had a mild systemic reaction (angioedema) after a Vespula sting" 04/01/2006 - "Systemic immunotherapy with a Tricophyton/Candida vaccin was completely cleared the urticaria/angioedema and decreased specific IgE from more than 100 KUA/I to 7.6 to Tricophyton and from 4.5 KUA/I to 0.7 KUA to Candida after immunotherapy." 06/01/2008 - "New therapeutic approaches to AD, urticaria, and angioedema have been reported, including use of sublingual immunotherapy, anti-IgE, and a kallikrein inhibitor." 05/01/2000 - "CONCLUSIONS: Pretreatment with fexofenadine during venom immunotherapy reduces local allergic reactions and generalized symptoms of the urticaria and angioedema type." Order ALL the reference details at left...
3.	Ovariectomy (Oophorectomy) 10/01/2004 - "She had suffered recurrent episodes of angioedema over a long period and had been scheduled for elective caesarean hysterectomy and bilateral oophorectomy at 37 weeks' gestation" 10/01/2004 - "In most cases surgical oophorectomy provides prolonged relief from the recurrent angioedema and dermatological manifestations that are typical of autoimmune progesterone dermatitis" Order ALL the reference details at left...
4.	Drug Therapy (Chemotherapy) 08/01/2007 - "The current pharmacotherapy of nonallergic angioedema is not satisfactory, thus requiring the identification of effective agents in clinical trials" 11/01/2007 - "Novel pharmacotherapies may allow a causal treatment of the ACE-inhibitor induced angioedema in the future." 12/01/1993 - "Two of the patients initially did not require specific anti-lymphoma therapy and responded to therapy with an attenuated androgen; in the third patient, splenectomy and cytotoxic chemotherapy led to resolution of the acquired angioedema" 09/01/2002 - "Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used?" 01/01/2002 - "Thus, initial pharmacotherapy for systolic heart failure should consist of: maximal tolerated dosages of ACE inhibitors;ARBs if ACE inhibitors are not tolerated because of intractable cough or angioedema;adequate dosages of hydralazine and isosorbide dinitrate if ACE inhibitors or ARBs are not tolerated; relatively low dosages of digoxin (serum concentrations of < or = 1.0 ng/dl) if not contraindicated; and diuretics to relieve congestive symptoms" Order ALL the reference details at left...
5.	Self Administration (Administration, Self) 04/01/2006 - "OBJECTIVE: The aim of this study was to investigate the feasibility, efficacy, and safety of on-demand and prophylactic self-administration of C1-inhibitor concentrate in patients with frequent attacks of angioedema" 04/01/2006 - "CLINICAL IMPLICATIONS: Self-administration of C1-inhibitor concentrate could be a valuable and convenient treatment modality to prevent or treat angioedema attacks in patients with C1-inhibitor deficiency." 04/01/2006 - "CONCLUSION: Intravenous self-administration of C1-inhibitor concentrate is a feasible and safe option and results in more rapid and more effective treatment or prevention of severe angioedema attacks in patients with C1-inhibitor deficiency" 04/01/2006 - "In the prophylaxis group self-administration of C1-inhibitor concentrate decreased the angioedema attack rate from 4.0 to 0.3 attacks per month" 04/01/2006 - "Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Angioedema

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 32 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>